ND-2110
ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM) . ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations, . ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models[1].
Product Specifications
CAS Number
[1388894-17-4]
UNSPSC
12352005
Target
IRAK
Type
Reference compound
Related Pathways
Immunology/Inflammation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/nd-2110.html
Smiles
O=C(N)C[C@H]1CCC2=C1C3=C(O[C@@H]4CC[C@@H](N5CCOCC5)CC4)N=CN=C3S2
Molecular Formula
C21H28N4O3S
Molecular Weight
416.54
References & Citations
[1]Kelly PN, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015 Dec 14;212 (13) :2189-201.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1230306-01 0.02 mg (E-Coli)
Recombinant Coxiella burnetii CCA-adding enzyme (cca)
Ask
View Details MBS1230306-02 0.02 mg (Yeast)
Recombinant Coxiella burnetii CCA-adding enzyme (cca)
Ask
View Details MBS1230306-03 0.1 mg (E-Coli)
Recombinant Coxiella burnetii CCA-adding enzyme (cca)
Ask
View Details MBS1230306-05 0.02 mg (Baculovirus)
Recombinant Coxiella burnetii CCA-adding enzyme (cca)
Ask
View Details 
MBS1230306-06 0.02 mg (Mammalian-Cell)
Recombinant Coxiella burnetii CCA-adding enzyme (cca)
Ask
View Details